Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by Telmisartan/Amlodipine Combination

Trial Profile

Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by Telmisartan/Amlodipine Combination

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2016

At a glance

  • Drugs Amlodipine/telmisartan/hydrochlorothiazide (Primary) ; Amlodipine/telmisartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Ildong Pharmaceutical
  • Most Recent Events

    • 23 Nov 2016 Status changed from recruiting to completed.
    • 28 Apr 2016 The protocol has been amended with the change in the dosage of Hydrochlorothiazide from 12.5 to 25mg 1 Tab.QD
    • 28 Apr 2016 Planned number of patients changed from 150 to 300.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top